Chair’s Opening Remarks – Exploring the Clinical Trials & Comparisons of the Current Trastuzumab-Based Anti-HER2 ADCs
Time: 8:50 am
day: Day One
Speakers:
I head a translational research lab in Discovery Oncology at Genentech that investigates cell membrane receptors as targets for development of cancer therapeutics, with emphasis on the HER2/erbB2 pathway. Our early research efforts focused on biology and preclinical development of anti-HER2 antibodies for HER2-amplified breast cancer. This work contributed to the development and approval of…Read more